{"protocolSection":{"identificationModule":{"nctId":"NCT06479616","orgStudyIdInfo":{"id":"CS-101-04"},"organization":{"fullName":"Children's Hospital of Fudan University","class":"OTHER"},"briefTitle":"A Long-term Follow-up Study in Participants Who Received CS-101","officialTitle":"A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-24","studyFirstSubmitQcDate":"2024-06-24","studyFirstPostDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-24","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Children's Hospital of Fudan University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)","detailedDescription":"This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189) .\n\nSubjects in the CS-101-03 study will be entered into long-term follow-up of this study up to 2 years post-infusion at the completion of the last (6-month) follow-up visit after treatment with CS-101 Injection."},"conditionsModule":{"conditions":["Beta-Thalassemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"OTHER","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":5,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"long term follow up","type":"EXPERIMENTAL","description":"All participants who complete CS-101-03(NCT0606518) studie after CS-101 infusion will be asked to participate in this long-term follow-up study.","interventionNames":["Genetic: CS-101"]}],"interventions":[{"type":"GENETIC","name":"CS-101","description":"Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique","armGroupLabels":["long term follow up"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Frequency and severity of SAEs and CS-101 related AES as assessed by CTCAE v5.0","description":"CommonTerminology Criteria for Adverse Events（CTCAE）has 5 levels of AE determination, increasing in severity as the level increases","timeFrame":"Signing of informed consent up to 2 years post CS-101 infusion"},{"measure":"Occurrence of all-cause death","timeFrame":"Signing of informed consent up to 2 years post CS-101 infusion"},{"measure":"New malignancies and hematologic disorders","description":"Based on ICD-11","timeFrame":"Signing of informed consent up to 2 years post CS-101 infusion"},{"measure":"Occurrence of achieving transfusion independence for at least 12 consecutive months","timeFrame":"From 3 months after last RBC transfusion up to 2 years post CS-101 infusion"}],"secondaryOutcomes":[{"measure":"Change in fetal hemoglobin(HbF) concentration over time","timeFrame":"up to 2 years post-CS-101 infusion"},{"measure":"Change in total hemoglobin(Hb) concentration over time","timeFrame":"up to 2 years post-CS-101 infusion"},{"measure":"Chimerism level in Peripheral blood and bone marrow Proportion of alleles with intended genetic modification in peripheral blood leukocytes and bone marrow over time","description":"Proportion of alleles with intended genetic modification in peripheral blood leukocytes and bone marrow over time","timeFrame":"up to 2 years post-CS-101 infusion"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form\n* Participants must have received CS-101 infusion in last IIT study\n\nExclusion Criteria:\n\n* There are no exclusion criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"centralContacts":[{"name":"Xiaowen Zhai, M.D.","role":"CONTACT","phone":"+86-021-64931126","email":"zhaixiaowendy@163.com"},{"name":"Zifeng Li, M.S.","role":"CONTACT","phone":"+86-13920704768","email":"zfli18@fudan.edu.cn"}],"overallOfficials":[{"name":"Xiaowen Zhai, M.D.","affiliation":"Children's Hospital of Fudan University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Children's Hospital of Fudan University","status":"RECRUITING","city":"Shanghai","state":"Shanghai","zip":"201102","country":"China","contacts":[{"name":"Zifeng Li, M.S.","role":"CONTACT","phone":"+86-13920704768","email":"zfli18@fudan.edu.cn"}],"geoPoint":{"lat":31.22222,"lon":121.45806}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000013789","term":"Thalassemia"},{"id":"D000017086","term":"beta-Thalassemia"}],"ancestors":[{"id":"D000000745","term":"Anemia, Hemolytic, Congenital"},{"id":"D000000743","term":"Anemia, Hemolytic"},{"id":"D000000740","term":"Anemia"},{"id":"D000006402","term":"Hematologic Diseases"},{"id":"D000006453","term":"Hemoglobinopathies"},{"id":"D000030342","term":"Genetic Diseases, Inborn"}],"browseLeaves":[{"id":"M16557","name":"Thalassemia","asFound":"Thalassemia","relevance":"HIGH"},{"id":"M19408","name":"beta-Thalassemia","asFound":"Beta Thalassemia","relevance":"HIGH"},{"id":"M4070","name":"Anemia","relevance":"LOW"},{"id":"M9547","name":"Hemolysis","relevance":"LOW"},{"id":"M4073","name":"Anemia, Hemolytic","relevance":"LOW"},{"id":"M4075","name":"Anemia, Hemolytic, Congenital","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"},{"id":"M9539","name":"Hemoglobinopathies","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"T5622","name":"Thalassemia","asFound":"Thalassemia","relevance":"HIGH"},{"id":"T737","name":"Beta-thalassemia","asFound":"Beta Thalassemia","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}